TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04657770

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: The telerehabilitation system will deliver rehabilitation treatment sessions via a secured internet-connected computer. A major component of the system is the use of games to promote therapeutically relevant movements. The subject will perform daily assigned remote-based telerehabilitation games and exercises and 5 minutes of stroke education, all guided by the telerehabilitation system. During some of the sessions, therapists will initiate a videoconference with the subject's telerehabilitation system to discuss progress, issues, and revise treatment plans as needed.
Study: NCT05177588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Metformin 2000 mg/day
Study: NCT05908266

Intervention type: OTHER
Intervention: Reaching movements
Description: Participants will be instructed to perform reaching movements by moving the handle of a robotic arm mounted with a virtual reality display.

Intervention type: OTHER
Intervention: Reaching movements
Description: Participants will be instructed to perform reaching movements by moving the handle of a robotic arm mounted with a virtual reality display.

Intervention type: OTHER
Intervention: Disease Assessment
Description: Disease stage assessed by trained professionals
Study: NCT04915534

Intervention type: DEVICE
Group type: OTHER
Intervention: Ambu® AuraGain™ Laryngeal Mask (LM)
Description: Depending on the gender and randomization, the LM is either blocked with 45 cmH2O or with 60 cmH2O cuff pressure. Following general anaesthesia, patients are questioned for postop complications, with focus on postoperative sore throat and hoarseness.

Intervention type: DEVICE
Group type: OTHER
Intervention: Ambu® AuraGain™ Laryngeal Mask (LM)
Description: Depending on the gender and randomization, the LM is either blocked with 45 cmH2O or with 60 cmH2O cuff pressure. Following general anaesthesia, patients are questioned for postop complications, with focus on postoperative sore throat and hoarseness.

Intervention type: DEVICE
Group type: OTHER
Intervention: Ambu® AuraGain™ Laryngeal Mask (LM)
Description: Depending on the gender and randomization, the LM is either blocked with 45 cmH2O or with 60 cmH2O cuff pressure. Following general anaesthesia, patients are questioned for postop complications, with focus on postoperative sore throat and hoarseness.
Study: NCT05488821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLH11906
Description: QLH11906 only
Study: NCT05158400

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound examination on the hand
Study: NCT05499520

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Culturally Tailored Anti-Smoking Messages
Description: Anti-smoking messages will be administered online via a Qualtrics survey.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Culturally Tailored Anti-Smoking Messages
Description: Anti-smoking messages will be administered online via a Qualtrics survey.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Culturally Tailored Anti-Smoking Messages
Description: Anti-smoking messages will be administered online via a Qualtrics survey.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Culturally Tailored Anti-Smoking Messages
Description: Anti-smoking messages will be administered online via a Qualtrics survey.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Culturally Tailored Anti-Smoking Messages
Description: Anti-smoking messages will be administered online via a Qualtrics survey.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Culturally Tailored Anti-Smoking Messages
Description: Anti-smoking messages will be administered online via a Qualtrics survey.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Culturally Tailored Anti-Smoking Messages
Description: Anti-smoking messages will be administered online via a Qualtrics survey.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Culturally Tailored Anti-Smoking Messages
Description: Anti-smoking messages will be administered online via a Qualtrics survey.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Culturally Tailored Anti-Smoking Messages
Description: Anti-smoking messages will be administered online via a Qualtrics survey.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Culturally Tailored Anti-Smoking Messages
Description: Anti-smoking messages will be administered online via a Qualtrics survey.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Culturally Tailored Anti-Smoking Messages
Description: Anti-smoking messages will be administered online via a Qualtrics survey.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Culturally Tailored Anti-Smoking Messages
Description: Anti-smoking messages will be administered online via a Qualtrics survey.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Culturally Tailored Anti-Smoking Messages
Description: Anti-smoking messages will be administered online via a Qualtrics survey.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Culturally Tailored Anti-Smoking Messages
Description: Anti-smoking messages will be administered online via a Qualtrics survey.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Culturally Tailored Anti-Smoking Messages
Description: Anti-smoking messages will be administered online via a Qualtrics survey.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Culturally Tailored Anti-Smoking Messages
Description: Anti-smoking messages will be administered online via a Qualtrics survey.
Study: NCT05406193

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-centred complex intervention in complicated multimorbidity (CIM2)
Description: CIM2 is the second version of the Patient-centred complex intervention in complicated multimorbidity
Study: NCT04915534

Intervention type: DEVICE
Group type: OTHER
Intervention: Ambu® AuraGain™ Laryngeal Mask (LM)
Description: Depending on the gender and randomization, the LM is either blocked with 45 cmH2O or with 60 cmH2O cuff pressure. Following general anaesthesia, patients are questioned for postop complications, with focus on postoperative sore throat and hoarseness.
Study: NCT04476329

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib 40 MG
Description: Regorafenib (BAY 73-4506) is an oral small molecule tyrosine kinase inhibitor (TKI) that potently blocks multiple protein kinases, including kinases involved in tumor angiogenesis (vascular endothelial growth factor receptor \[VEGFR\] 1, 2, 3, Tyrosine kinase with immunoglobulin-like and epidermal growth factor-like domains 2 \[TIE2\]), stem cell growth factor receptor (KIT, rearranged during transfection \[RET\], p38-alpha, a member of the mitogen activated protein kinase \[MAPK\] family, proto-oncogene c-RAF \[c-RAF\], proto-oncogene BRAF \[BRAF\], BRAFV600E), metastasis (VEGFR3, platelet-derived growth factor receptor \[PDGFR\], fibroblast growth factor receptor1 \[FGFR1\]) and tumor immunity (colony stimulating factor 1 receptor \[CSF1R\]).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib 40 MG
Description: Regorafenib (BAY 73-4506) is an oral small molecule tyrosine kinase inhibitor (TKI) that potently blocks multiple protein kinases, including kinases involved in tumor angiogenesis (vascular endothelial growth factor receptor \[VEGFR\] 1, 2, 3, Tyrosine kinase with immunoglobulin-like and epidermal growth factor-like domains 2 \[TIE2\]), stem cell growth factor receptor (KIT, rearranged during transfection \[RET\], p38-alpha, a member of the mitogen activated protein kinase \[MAPK\] family, proto-oncogene c-RAF \[c-RAF\], proto-oncogene BRAF \[BRAF\], BRAFV600E), metastasis (VEGFR3, platelet-derived growth factor receptor \[PDGFR\], fibroblast growth factor receptor1 \[FGFR1\]) and tumor immunity (colony stimulating factor 1 receptor \[CSF1R\]).
Study: NCT05565664

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine hydrochloride
Description: Ketamine hydrochloride will be made in a 20 ml syringe in a concentration of 1.25 mg/ml. Patients will receive IV ketamine hydrochloride in a dose of 0.5 mg/kg (equivalent to 0.4 ml/kg) over 10 min.~The coordinator of the study will prepare blinded syringes for each group, while the anesthetist who will be in charge of anesthetic management during the operation will be unaware of the study medication.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate
Description: A 20 ml syringe will contain magnesium sulphate in a concentration 100 mg/ml (10%). Patients will receive 40 mg/kg of IV magnesium sulphate (equivalent to 0.4 ml/kg) over 10 min.~The coordinator of the study will prepare blinded syringes for each group, while the anesthetist who will be in charge of anesthetic management during the operation will be unaware of the study medication.
Study: NCT04840264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 25 mg/square metre, D1, D8, D15, repeat every 4 weeks.
Study: NCT06428890

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Grape Seed Extract
Description: dietary supplements that rich in polyphenolic compounds

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Grape Seed Extract
Description: dietary supplements that rich in polyphenolic compounds

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Starch

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Starch
Study: NCT05825066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: The intervention will be administered on an outpatient basis. The patients on this study will begin treatment with GA for one month and then transition to mFFX for one month.~The patient will come off of the sequence study intervention if the imaging after the 2nd month shows unequivocal progression. After four months of sequential neoadjuvant therapy the patient will come off study and can proceed to surgery, radiation, or extended course of chemotherapy as determined by the multidisciplinary tumor board consensus or the treating physician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: The intervention will be administered on an outpatient basis. The patients on this study will begin treatment with GA for one month and then transition to mFFX for one month.~The patient will come off of the sequence study intervention if the imaging after the 2nd month shows unequivocal progression. After four months of sequential neoadjuvant therapy the patient will come off study and can proceed to surgery, radiation, or extended course of chemotherapy as determined by the multidisciplinary tumor board consensus or the treating physician.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiological Assessments
Description: CT imaging of chest abdomen and pelvis will be performed every 8 weeks. MRI may be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX
Description: The intervention will be administered on an outpatient basis. The patients on this study will begin treatment with GA for one month and then transition to mFFX for one month.~The patient will come off of the sequence study intervention if the imaging after the 2nd month shows unequivocal progression. After four months of sequential neoadjuvant therapy the patient will come off study and can proceed to surgery, radiation, or extended course of chemotherapy as determined by the multidisciplinary tumor board consensus or the treating physician.
Study: NCT04840264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 25 mg/square metre, D1, D8, D15, repeat every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 25 mg/square metre, D1, D8, D15, repeat every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/msquare metre, D1, D15, repeat every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/msquare metre, D1, D15, repeat every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/msquare metre, D1, D15, repeat every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 1200 mg/square metre, D1, D8, D15, repeat every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 1200 mg/square metre, D1, D8, D15, repeat every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 1200 mg/square metre, D1, D8, D15, repeat every 4 weeks.
Study: NCT05336708

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure Group
Description: In the acupressure group, acupressure will be applied to the heart meridian 7th point (HT7), large intestine meridian 4th point (LI4), stomach meridian 36th point (ST36) and spleen meridian 6th point (SP6). After pressing each point for a certain period of time, a total of two minutes of rest periods will be applied by the researcher.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Acupressure Group
Description: In the sham acupressure group, acupressure will be applied on the bone region where the meridians do not pass, approximately 1-1.5 cm away from the HT7, LI4, ST36, SP6 points. The application process will continue in the same way with acupressure group and the pressure intensity will be less.
Study: NCT05101044

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance-based Behavioral Therapy (ABBT) Intervention
Description: This acceptance-based behavioral therapy (ABBT) intervention intends to enhance retention in HIV care for people who use substances by targeting stigma. ABBT promotes an accepting stance towards life's challenges and encourages participants to thoughtfully disclose the serostatus and/or substance abuse problems as a behavioral step towards challenging stigmatization fears. The central hypothesis is that increased tolerance of stigmatization, facilitated through increased acceptance of HIV status and substance use behaviors, will increase PWH's longitudinal commitment to care.
Study: NCT04793347

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: shock master (shock waves device)
Description: device produces shock waves
Study: NCT05503745

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CBT-F+MIT
Description: The aim is to develop healthier strategies for managing negative thoughts and feelings antecedent to ED and for engaging patients in social interactions that meet their relational basic wishes. They will thus understand that perfectionism and the need for control they experience through ED are coping strategies developed within interpersonal patterns of interaction with significant others, where low self-esteem and emotive dysregulation play a central role. MIT aims to improve individuals' capacity to make sense of their own affect and cognitions and become aware of being driven by maladaptive, rigid and biased schemas about self and others, to form a richer understanding of the mind of the others and use this knowledge to react in more adaptive ways to social difficulties or evolutionary selected wishes. MIT also enables individuals to reflect on how these schemas may act as triggers for ED behavior and to develop more effective coping strategies in face of interpersonal stressors.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CBT-E
Description: In the first Stage, the treatment will be focused on achieving a shared understanding of the patient's eating disorder and the related maintenance factors. In this phase the patient will be helped to regulate and stabilize his eating habits and so to address his weight concerns. In the second stage, progress made is reviewed in detail. In the third stage, the sessions will be focused on the central processes that are maintaining the psychopathology of the patient's eating disorder. In particular, this involves in addressing concerns about weight and body shape, cognitive and caloric dietary restriction, events and emotions that affect nutrition. In phase three and four clinical perfection, low global self-esteem, intolerance of emotions and interpersonal difficulties are also addressed. Towards the end of the third stage and during the fourth stage, procedures will be also implemented to minimize the risk of short- and long-term relapse.
Study: NCT04531709

Intervention type: OTHER
Intervention: Comprehensive Score for financial toxicity (COST)
Description: Measure indirect and direct health care cost that burden patients and their loved ones.

Intervention type: OTHER
Intervention: Comprehensive Score for financial toxicity (COST)
Description: Measure indirect and direct health care cost that burden patients and their loved ones.

Intervention type: OTHER
Intervention: Functional Assessment of Cancer Therapy: General (FACT-G)
Description: General quality of life instrument

Intervention type: OTHER
Intervention: Functional Assessment of Cancer Therapy: General (FACT-G)
Description: General quality of life instrument

Intervention type: OTHER
Intervention: EORTC QLQ C-30
Description: Assess quality of life in cancer patients

Intervention type: OTHER
Intervention: EORTC QLQ C-30
Description: Assess quality of life in cancer patients

Intervention type: OTHER
Intervention: EORTC QLQ-TC26.
Description: To measure disease and treatment related quality of life issues relevant to testicular cancer patients that were not explored in the QLQ-C30 questionnaire.

Intervention type: OTHER
Intervention: EORTC QLQ-TC26.
Description: To measure disease and treatment related quality of life issues relevant to testicular cancer patients that were not explored in the QLQ-C30 questionnaire.
Study: NCT05917431

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SBRT plus tislelizumab and regorafenib
Description: Participants will receive SBRT plus tislelizumab and regorafenib concurrently
Study: NCT05272345

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sexual therapy
Description: In sexual therapy; A total of 4 sessions of therapy were initiated with the patients, one session per week for 1 month.
Study: NCT06154967

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: tereotactic body radiotherapy
Description: In second-line and later treatment, the treatment regimen of SBRT combined with tislelizumab is used
Study: NCT06108102

Intervention type: OTHER
Intervention: Presence of stroke, either ischemic or hemorrhagic (intracerebral and subarachnoid)
Description: Presence of ischemic or hemorrhagic stroke confirmed by neuroimaging and clinical diagnosis

Intervention type: OTHER
Intervention: Presence of stroke, either ischemic or hemorrhagic (intracerebral and subarachnoid)
Description: Presence of ischemic or hemorrhagic stroke confirmed by neuroimaging and clinical diagnosis
Study: NCT05247788

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blood alcohol concentration (BAC) discrimination training
Description: Subjects will receive 0.65 g/kg alcohol to yield a peak BAC of 85 mg/dl (0.085%). They will be trained to accurately estimate their BAC using the Body Scan Exercise with BAC feedback.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Performance feedback training
Description: This training element targets the driver's self-efficacy by increasing their awareness of the behavioral impairing effects of alcohol that are experienced at BACs at and even below the legal limit (50-80 mg/dl).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood alcohol concentration (BAC) discrimination training for controls
Description: Subjects will receive 0.65 g/kg alcohol to yield a peak BAC of 85 mg/dl (0.085%). They will be given a general Body Scan Exercise with no feedback.
Study: NCT05944536

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balance Exercises (BE)
Description: Each exercise was performed with 10 repetitions for both lower limbs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BE + Dual Task
Description: Cognitive and motor secondary tasks were given
Study: NCT06550167

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nano-PSO, Pomegranate seed oil (omega-5)
Description: During the intervention, Nano-PSO dietary supplement will be administered to the participants in the assigned group.~Participants will be followed before and after treatment to assess the effects of Nano-PSO on cognitive status, serum concentrations of trophic factors, and other relevant parameters . This randomized, double-blind, controlled clinical trial design allows for a rigorous evaluation of the potential benefits of Nano-PSO in patients with substance use disorders. The study aims to provide valuable insights into the neuroprotective and cognitive-enhancing properties of Nano-PSO in this population.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: In this arm of the study the participants will receive a placebo as a control treatment . The placebo is essential in clinical trials to compare the effects of the active intervention (Nano-PSO) with those of an inert substance.
Study: NCT04830098

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal stabilization exercises
Description: It will be given stabilization exercises for a total of 18 sessions, 3 times a week for 6 weeks, each session for 45 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal stabilization exercises
Description: It will be given stabilization exercises for a total of 18 sessions, 3 times a week for 6 weeks, each session for 45 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chiropractic manipulation
Description: It will be applied high-speed low-amplitude (HVLA) chiropractic manipulation for a total of 6 sessions, once a week for 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chiropractic manipulation
Description: It will be applied high-speed low-amplitude (HVLA) chiropractic manipulation for a total of 6 sessions, once a week for 6 weeks.
Study: NCT04992858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT053PTSA
Description: CT053PTSA will be administered orally once a day
Study: NCT04451213

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI head
Description: MRI head
Study: NCT05373069

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mechanical ischemic preconditioning of diep-type flap
Description: Mechanical ischemic preconditioning: Performing series of reperfusion ischemia on the flap pedicle, before cold ischemia of the flap (flap harvesting before vascular mechanical anastomoses at the recipient site)~* 10 min of clamping with single-use microvascular forceps~* 10 min declamping~* 10 min of tightening with pliers~* 10 min declamping Either preconditioning for 40 minutes, simulating 2 cycles of ischemia reperfusion prior to flap harvesting and cold ischemia before revascularization.
Study: NCT05637814

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SpO2/PIx Measurement and ML Algorithm
Description: Right upper and any lower extremity oxygen saturation (SpO2) and perfusion index (PIx) will be measured and an online ML inference model will be used to classify a newborn as healthy versus CCHD as new pulse oximetry data is collected.